The document provides an update on the Genome in a Bottle (GIAB) Consortium. Key points include:
- New benchmark sets have been developed for mosaic variants, tandem repeats, and chromosomes X and Y using whole genome assemblies.
- Additional reference materials and samples are available, including a new tumor/normal cell line and over 50 products based on broadly consented genomes.
- Benchmarking methods are improving to better evaluate variant calling, including for structural variants and different data types like RNA sequencing.
- Future plans include developing more somatic benchmarks, assembling the HG002 genome to near perfection, and a searchable public data registry.
1. Schizophrenia is a chronic neuropsychiatric disorder affecting about 1% of the world's population that imposes a large economic burden.
2. While the exact causes remain unclear, current research suggests schizophrenia involves alterations in brain development and circuits during early development. Genetics also play a role as risk factors.
3. Recent advances in treatment include new atypical antipsychotic medications that target both dopamine and serotonin receptors, as well as research into alternative treatments targeting negative symptoms, cognitive impairments, and underlying neuropathology and metabolic abnormalities.
The document provides an update on the Genome in a Bottle (GIAB) Consortium. Key points include:
- New benchmark sets have been developed for mosaic variants, tandem repeats, and chromosomes X and Y using whole genome assemblies.
- Additional reference materials and samples are available, including a new tumor/normal cell line and over 50 products based on broadly consented genomes.
- Benchmarking methods are improving to better evaluate variant calling, including for structural variants and different data types like RNA sequencing.
- Future plans include developing more somatic benchmarks, assembling the HG002 genome to near perfection, and a searchable public data registry.
1. Schizophrenia is a chronic neuropsychiatric disorder affecting about 1% of the world's population that imposes a large economic burden.
2. While the exact causes remain unclear, current research suggests schizophrenia involves alterations in brain development and circuits during early development. Genetics also play a role as risk factors.
3. Recent advances in treatment include new atypical antipsychotic medications that target both dopamine and serotonin receptors, as well as research into alternative treatments targeting negative symptoms, cognitive impairments, and underlying neuropathology and metabolic abnormalities.
Molecular Marker-assisted Breeding in RiceFOODCROPS
?
1. The document discusses molecular marker-assisted breeding in rice. It provides details on the expertise and experiences of Dr. Jian-Long Xu in molecular rice breeding including allele mining and marker-assisted selection.
2. Marker-assisted selection is described as a method to select phenotypes based on the genotype of linked markers rather than the target gene itself. The advantages of MAS include time and cost savings compared to traditional field trials.
3. Requirements for large-scale application of MAS include validation of QTL in breeding materials, efficient genotyping protocols, and decision support tools for breeders.
The document contains biographical information about several famous people presented as puzzles to guess who each person is based on clues about their life and career. The people described are The Rock, Albert Einstein, Bill Gates, Michael Phelps, and Michael Jackson. For each, clues are given about their date of birth, family background, achievements, and occupations to allow the reader to deduce who the person is.
Industrial Programming Language (IPL) Reference Manual for Quantities, Logic/...Alkis Vazacopoulos
?
The IPL code can be programmed in any computer programming language that can interact with dynamic link or shared object libraries and then can be used to call our IMPL modeling and solving platform. IMPL is an acronym for Industrial Modeling and Programming Language provided by Industrial Algorithms LLC. The IPL code allows the user to configure and capture the necessary data to model and solve large-scale and complex industrial optimization problems (IOP's) such as planning, scheduling, control and data reconciliation and regression in either off or on-line environments. IPL, also known as the IMPL Interacter, is a complement to IML (known as the IMPL Interfacer) which means that they can be combined together in any arrangement or combination. That is, a portion of the model can be configured in IML/IPL and the remaining portion can be configured in IPL/IML. In addition, all terminology and nomenclature used in IPL are consistent with IML given that their data is interchangeable and exchangeable. Ultimately, once all of the static and dynamic model data have been configured using IML and IPL, then IMPL’s Modeler will create or generate the necessary IMPL sets, lists, parameters, formulas, variables and constraints (as well as the derivatives and expressions).
All integers are 4-bytes (long), all reals are 8-bytes (double precision) and all strings are 64-bytes unless otherwise stated. The return status for the integer functions is zero (0) for successful and non-zero for unsuccessful which usually implies that the unit-operation-port-state names and/or the quality name was not recognized.
This document discusses defining one's leadership legacy. It encourages leaders to clarify what legacy means to them, determine goals to accomplish that legacy, and develop an action plan with first steps. Attendees are asked to pair up and discuss their proudest accomplishments, why leaving a legacy is important, and their strengths to make their campus better. The document provides tips for effective goal setting, including making goals specific, measurable, attainable, realistic, timely and ethical. Overall it focuses on helping leaders reflect on their impact and develop goals and plans to further their leadership legacy.
NGS由来ゲノムワイド多型マーカ構築とそのRDF注釈情報統合化
Eli Kaminuma1, Takatomo Fujisawa1, Takako Mochizuki1, Yasuhiro Tanizawa1, Atsushi Toyoda1, Asao Fujiyama1, Nori Kurata1, Tokurou Shimizu2, Yasukazu Nakamura1
1. National Institute of Genetics, SOKENDAI ; 1111 Yata, Mishima, Shizuoka, 411-8540 Japan.
2. National Institute of Fruit Tree Science; Okitsu Nakacho, Shizuoka, 424-0292 Japan
BMB2013(第36回日本分子生物学会年会)ポスター 3P-0030
2013年12月5日